论文部分内容阅读
目的 :观察生脉注射液联合华蟾素注射液对结直肠癌术后复发的防治作用。方法 :将60例Ⅲ期结直肠癌根治术后患者随机分为2组各30例,对照组常规行FOLFOX4化疗方案,观察组在FOLFOX4化疗方案的基础上,以生脉注射液联合华蟾素注射液静脉滴注,连续7天为1疗程,共6疗程。随访5年。以术后的第1、2、3、5年为观察时间点,记录2组的复发率及生存率,并记录2组患者的复发时间。结果:5年随访期中,对照组复发7例,观察组复发3例,平均复发时间观察组为(28.74±9.34)月,对照组为(17.65±6.21)月,观察组平均复发时间较对照组推迟约10月,差异有统计学意义(P<0.05)。观察组第1、2、3、5年的复发率均低于对照组,其中第2年的复发率为3.45%,明显低于对照组(21.43%),差异有统计学意义(P<0.05)。观察组第2、3、5年的生存率均高于对照组,但差异均无统计学意义(P>0.05)。结论:生脉注射液联合华蟾素注射液在一定程度上推延了结直肠癌术后复发的时间,降低了复发率。
Objective: To observe the prevention and treatment of Shengmai injection combined with cinobufacini injection on postoperative recurrence of colorectal cancer. Methods: Sixty patients with stage Ⅲ colorectal cancer after radical operation were randomly divided into two groups of 30 patients. The control group received routine FOLFOX4 chemotherapy. On the basis of the FOLFOX4 chemotherapy regimen, the observation group received Shengmai injection combined with cinobufacini Injection intravenous infusion for 7 days for a course of treatment, a total of 6 courses. Followed up for 5 years. The postoperative 1, 2, 3, 5 years as the observation time point, record the recurrence rate and survival rate of 2 groups, and record the recurrence time of 2 groups of patients. Results: In the 5-year follow-up period, the control group recurred in 7 cases and the observation group recurred in 3 cases. The mean recurrent time was 28.74 ± 9.34 months in the observation group and 17.65 ± 6.21 months in the control group. The average recurrence time in the observation group was significantly higher than that in the control group Delays about October, the difference was statistically significant (P <0.05). The recurrence rates in the observation group at 1, 2, 3 and 5 years were lower than those in the control group, of which the recurrence rate in the second year was 3.45%, which was significantly lower than that in the control group (21.43%), with statistical significance (P <0.05 ). Survival rates in the second, third and fifth year of the observation group were higher than those in the control group, but the differences were not statistically significant (P> 0.05). Conclusion: Shengmai injection combined with cinobufacini injection delayed the recurrence time of colorectal cancer to a certain extent and reduced the recurrence rate.